Luminopia develops a binocular therapy using a VR headset to treat amblyopia in children aged 4-7 by streaming engaging content for one hour a day, six days a week. This FDA-approved treatment has demonstrated significant vision improvement in clinical trials, making it a more enjoyable alternative to traditional patching methods.
Funding
$32.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional amblyopia treatments, such as eye patching, can be difficult for children to adhere to, leading to inconsistent therapy and potentially limiting vision improvement. These conventional methods often face challenges with patient compliance due to discomfort and social stigma.
Solution
Luminopia offers an FDA-approved digital therapeutic for amblyopia that uses a virtual reality (VR) headset to stream engaging TV content, providing a more enjoyable and effective treatment alternative to traditional patching. The binocular therapy works by modifying the streamed content to encourage the brain to strengthen the weaker eye while the child watches their favorite shows. This approach improves patient compliance and has demonstrated significant vision improvement in clinical trials, with treatment requiring only one hour a day, six days a week. The VR headset is provided to patients, making it a convenient and accessible at-home treatment option.
Target Audience
The primary target audience includes pediatric ophthalmologists and optometrists seeking innovative and engaging amblyopia treatments, as well as parents of children aged 4-12 diagnosed with amblyopia.
Features
- Binocular therapy delivered through a VR headset, streaming modified TV shows to stimulate both eyes
- FDA-approved treatment for amblyopia in children aged 4-12
- Clinically proven to improve vision with as little as one hour of use per day, six days a week
- Access to over 3,100 episodes from 75+ TV shows, eliminating the need for separate media subscriptions
- High patient engagement and compliance compared to traditional patching methods
- Prescription-based treatment, ensuring appropriate medical supervision
- Real-world evidence collected through the PUPiL registry to monitor treatment outcomes